Principal Investigator
David Baidal
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20251051
Clinical Trial Summary
A Phase 2b, Randomised, Double-Blind, Placebo-Controlled, Parallel-Arm Dose Finding Study Evaluating the Efficacy and Safety of SAB-142 for Delaying the Progression of Type 1 Diabetes (T1D) in Patients with Stage 3 New Onset of Type 1 Diabetes (NOT1D).
Phase
TBD
Funding Agency/Sponsor
Industry
Disease
Other